Sovenor 5. 10. 20 5mg. 10mg. 20mg Transdermal patches.
PDF Leaflet Revision Date: 18 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Chronic musculoskeletal pain of moderate to severe intensity.
Dosage (summary)
Initial dose: SOVENOR u00c6 5 (5 u03bcg/h), titrate every 3-7 days as needed.
Onset of Action / Duration
Onset: 12 hours, Duration: 7 days.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or lactation; risk of neonatal withdrawal syndrome.
Key Drug Interactions
- CNS depressants
- MAOIs
- Serotonergic agents
Contraindications
- Hypersensitivity to buprenorphine
- Severe hepatic impairment
- Myasthenia gravis
Common side effects
- Dizziness
- Constipation
- Nausea
- Application site reactions
Counselling Points
- Avoid direct heat on patch
- Monitor for signs of misuse
- Do not use with other CNS depressants
Serious warnings
- Respiratory depression
- Risk of addiction
- Serotonin syndrome
Important Disclaimer
The Sovenor 5. 10. 20 5mg. 10mg. 20mg Transdermal patches. professional information leaflet below is the property of Mundipharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
